CABACabaletta BioSigning up patients
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 24 (planned)
- Started
- Dec 17, 2024
- Main results expected
- Sep 2029
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To evaluate incidence and severity of adverse events (AEs)
Measured over: Up to 28 days after CABA-201 infusion
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06359041 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC